Home > Insider Trading > Filing (0001209191-12-019665)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1466301	Clovis Oncology Inc.	CLVS	Pharmaceutical Preparations (2834)	900475355

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
935463	H Paul Klingenstein	One Embarcadero Center, Suite 4000 San Francisco CA 94111		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-11-21	728,239	$0.00	728,239	No	4	C	Indirect	By Aberdare Ventures IV, L.P.
Common Stock	Acquisiton	2011-11-21	14,534	$0.00	14,534	No	4	C	Indirect	By Aberdare Partners IV, L.P.
Common Stock	Acquisiton	2011-11-21	158,439	$0.00	886,678	No	4	C	Indirect	By Aberdare Ventures IV, L.P.
Common Stock	Acquisiton	2011-11-21	3,162	$0.00	17,696	No	4	C	Indirect	By Aberdare Partners IV, L.P.
Common Stock	Acquisiton	2011-11-21	391,478	$13.00	1,278,156	No	4	P	Indirect	By Aberdare Ventures IV, L.P.
Common Stock	Acquisiton	2011-11-21	7,813	$13.00	25,509	No	4	P	Indirect	By Aberdare Partners IV, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Aberdare Ventures IV, L.P.
No	4	C	Indirect	By Aberdare Partners IV, L.P.
No	4	C	Indirect	By Aberdare Ventures IV, L.P.
No	4	C	Indirect	By Aberdare Partners IV, L.P.
No	4	P	Indirect	By Aberdare Ventures IV, L.P.
No	4	P	Indirect	By Aberdare Partners IV, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2011-11-21	507,119	$0.00	174,868	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2011-11-21	10,122	$0.00	3,490	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2011-11-21	507,119	$0.00	174,868	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2011-11-21	10,122	$0.00	3,490	$0.00
Common Stock	Series B Preferred Stock	Disposition	2011-11-21	1,097,661	$0.00	378,503	$0.00
Common Stock	Series B Preferred Stock	Disposition	2011-11-21	21,909	$0.00	7,554	$0.00
Common Stock	5% Convertible Note due 2012	Disposition	2011-11-21	0	$0.00	158,439	$0.00
Common Stock	5% Convertible Note due 2012	Disposition	2011-11-21	0	$0.00	3,162	$0.00

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
	No	4	C	Indirect
2012-05-25	No	4	C	Indirect
2012-05-25	No	4	C	Indirect

Footnotes

Each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 2.9 for 1 basis immediately prior to the closing of the Issuer's initial public offering on November 21, 2011. The shares have no expiration date.
The outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering at the Issuer's initial public offering price per share.
The Reporting Person is a Managing Director of Aberdare GP IV, L.L.C. ("Aberdare GP IV") which serves as the sole General Partner of Aberdare Ventures IV, L.P. ("Aberdare Ventures IV") and Aberdare Partners IV, L.P. ("Aberdare Partners IV"). As such, the Reporting Person shares voting and investment control over the securities owned by Aberdare Ventures IV and Aberdare Partners IV, and may be deemed to own beneficially the securities held by Aberdare Ventures IV and Aberdare Partners IV. Aberdare GP IV however owns no securities of the Issuer directly. The Reporting Person disclaims beneficial ownership of the shares held by Aberdare Ventures IV and Aberdare Partners IV except to the extent of his proportionate pecuniary interest therein.